EDX-MEDICAL
26.6.2024 10:22:30 CEST | Business Wire | Press release
EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse Ltd, to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.
cResponse™ is a groundbreaking platform that biologically assesses how an individual patient’s living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. This platform helps clinicians rapidly pinpoint optimal treatments, potentially saving lives, reducing treatment costs, and accelerating the discovery and development cycles for pharmaceutical companies seeking new cancer drugs.
The cResponse™ platform generates a report ranking selected cancer drugs based on their predicted effect on an individual patient’s tumour, demonstrating over 90% accuracy in clinical trials. The test can be augmented with rapid genomic sequencing to identify additional drug candidates for functional analysis. The entire process is powered by proprietary technologies and advanced AI algorithms. The platform technology has been refined and calibrated using thousands of cancer tissues, demonstrating its clinical utility and effectiveness through hundreds of cases in Israel and the UK. The cResponse™ test is performed at a United Kingdom Accreditation Service (UKAS) accredited lab in London and has also earned a CE mark for Europe, underscoring its regulatory approval and readiness for clinical use.
EDX Medical will initiate commercial activities to support the clinical use of the cResponse™ assay in the UK and Nordics with immediate effect and will explore broadening the agreement with Curesponse in due course.
Professor Sir Chris Evans, OBE, founder of EDX Medical plc, commented: “We are delighted to be increasing accessibility to this genuinely innovative and pioneering test which potentially offers tremendous benefit to those treating cancer and their patients. This product is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions.”
Dr Mike Hudson, CEO, EDX Medical plc, said: “We are very pleased to have been selected by Curesponse as their partner, and to be able to make their breakthrough assay available for our clients in the UK and Nordics. We consider cResponse™ to be an outstanding innovation in the fast-moving clinical cancer diagnostic landscape.”
Guy Neev, CEO of Curesponse Ltd, commented: “We are thrilled to partner with EDX Medical Group to bring our cResponse™ platform to patients and clinicians in the UK and Nordic countries. Our mission at Curesponse is to make this technology available to cancer patients to optimize treatment outcomes and save lives. This collaboration is a significant step toward achieving that goal. We look forward to working closely with the EDX Medical team to ensure the successful adoption and implementation of this groundbreaking decision support tool.”
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). www.edxmedical.com
About Curesponse Ltd. Curesponse is a pioneering leader in precision oncology. www.curesponse.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626860842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure20.8.2026 12:00:00 CEST | Press release
Leadership, operations and market development aligned across a global platform connecting Canada with Germany and other priority international markets Sanity Group integration marks the next phase of Organigram’s global growth strategy Finn Age Hänsel appointed President, Rest of World & Chief Strategy Officer Adrian Frenzel appointed Global Chief Operating Officer Tim Emberg to continue as President, Canada Organigram’s integrated supply and commercial network will span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia Sanity contributed approximately CAD$40 million to consolidated net revenue in Organigram’s most recent quarter, representing over 35% of net revenue, and was accretive to Adjusted EBITDA Sanity has demonstrated a strong growth trajectory, with quarterly revenue increasing 34% since December 31, 2025 to €25.5 million Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram” or the “Company”) today announced an important milestone in its
NTT DATA and Palo Alto Networks Sign Global Strategic Alliance to Accelerate Secure AI Transformation20.8.2026 12:00:00 CEST | Press release
First-of-its-kind global alliance combines AI-powered security innovation with enterprise-scale consulting and managed services Helps organizations navigate Frontier AI with integrated governance, threat intelligence and cybersecurity expertise Backed by co-innovation, shared engineering, coordinated global delivery and more than 2,000 Palo Alto Networks-certified professionals NTT DATA, a global leader in AI, digital business and technology services, and Palo Alto Networks (NASDAQ: PANW) today announced a multi-year strategic alliance designed to help organizations securely adopt AI, modernize cybersecurity, simplify complex technology environments and build cyber resilience for the AI era. As Palo Alto Networks first strategic alliance of this kind with a global systems integrator, the agreement, which targets $1 billion in joint business by the end of three years (2029), combines Palo Alto Networks AI-powered cybersecurity platforms with NTT DATA's consulting, engineering and manage
Packaging Redesigns See 4% Average Volume Lift, NIQ Finds20.8.2026 12:00:00 CEST | Press release
Liquid I.V., Hostess, Back to Nature, and five other brands named 2026 NIQ Design Impact Award winners NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named the winners of its ninth annual Design Impact Awards, recognizing eight package redesigns that combined stronger shopper experiences with measurable commercial performance. Across nearly a decade of NIQ Design Impact Award winners, recognized redesigns have been associated with an average volume increase of approximately 4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819712595/en/ NIQ Design Impact Awards 2026 The 2026 NIQ Design Impact Award Winners*:Aval French Cider (Parent Company: Aval Cider; Country: USA) Liquid I.V. (Parent Company: Unilever; Country: USA) Root & Splendor (Parent Company: Root & Splendor; Country: USA) Hostess Cakes (Parent Company: The J.M. Smucker Company; Country: USA) Back to Nature (Parent Company: Barilla Group;
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 09:00:00 CEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820387312/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 08:00:00 CEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819555366/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom